Skyrizi’s the limit? AbbVie forecasts blockbuster year for psoriasis drug

In newly released guidance Friday, AbbVie projected $1.2 billion in 2020 sales of Skyrizi after the drug far surpassed sales expectations in its first several months on the market.

Sales of Skyrizi risankizumab-rzaa climbed to $216 million in 4Q19, its second full quarter on the market, beating a 4Q19 consensus estimate of $142.7 million by 51%. That brought its full-year 2019 total to $355 million; AbbVie Inc. (NYSE:ABBV) launched the drug in May to treat psoriasis...